Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 27,848 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo and sham treatment Clear all

Conditions: Atopic Dermatitis
Interventions: Tilrekimig, Dupilumab, Placebo for Tilrekimig, Placebo for Dupilumab; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 1,375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 20
States / cities: Phoenix, Arizona • Bryant, Arkansas • Huntington Beach, California + 16 more

Conditions: COVID-19
Interventions: Dapsone 85 mg PO BID, Placebo 85 mg PO BID; Drug
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Other
Eligibility: 40 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • High Point, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Major Depressive Disorder, Psychotic Disorders
Interventions: Mifepristone, matching placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 23
States / cities: Pico Rivera, California • Riverside, California • San Diego, California + 20 more

Conditions: Pmm2-CDG, CDG1A
Interventions: Placebo, Acetazolamide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 4 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Alzheimer Disease
Interventions: AL002, Placebo; Drug
Lead sponsor: Alector Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Phoenix, Arizona • Rogers, Arkansas • Costa Mesa, California + 25 more

Conditions: Autism Spectrum Disorder
Interventions: intranasal oxytocin, oral probiotics, oral placebo; Drug · Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 3 Years to 25 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Memory Loss
Interventions: Donepezil Hydrochloride, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 54
States / cities: Albaster, Alabama • Mesa, Arizona • Peoria, Arizona + 51 more

Conditions: Age-related Macular Degeneration, Cataract
Interventions: Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA; Dietary Supplement · Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years to 85 Years
Enrollment: 4,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 91
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more

Conditions: Panic Disorder
Interventions: placebo, alprazolam XR; Other · Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 3
States / cities: Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin

Conditions: Cardiomyopathy, Renal Impairment
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: PF-06946860, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Anaheim, California

Conditions: RSV Infection
Interventions: Candidate vaccine, SCB-1019T, AREXVY, placebo; Biological · Other
Lead sponsor: Clover Biopharmaceuticals USA, LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 34
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more

Conditions: Refractory Chronic Cough
Interventions: 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]; Drug
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida

Conditions: Lymphoma
Interventions: Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 32
States / cities: Gilbert, Arizona • Campbell, California • Duarte, California + 29 more

Conditions: D008593
Interventions: Shatavari Root Extract, oral capsule; Dietary Supplement
Lead sponsor: Jacksonville University; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Obesity
Interventions: Coffee mannooligosaccharide, Coffee mannooligosaccharides; Dietary Supplement
Lead sponsor: Mondelēz International, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: carmoterol (CHF 4226), salmeterol, placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: Jonesboro, Arkansas • Fresno, California • San Diego, California + 19 more

Conditions: Healthy, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate, Naltrexone, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 35 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions: Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution; Drug
Lead sponsor: Florida A&M University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Healthy
Interventions: Ketamine and Org 25935, Placebo and Ketamine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Neuralgia, Postherpetic
Interventions: Lamictal in the treatment of Post-Herpetic Neuralgia; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 85 Years
Timeline: Started 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Heart Failure
Interventions: Ziltivekimab, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 4,874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 172
States / cities: Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more

Conditions: Epilepsy, Temporal Lobe
Interventions: Central Thalamic Stimulation, Hippocampal Stimulation; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Rochester, Minnesota • Lebanon, New Hampshire

Search by objective public record fields.

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

Acetazolamide Efficacy in Ataxia in PMM2-CDG

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

Age-Related Eye Disease Study 2 (AREDS2)

A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women

Study of Coffee Mannooligosaccharides for Weight Management

Dose Finding Study of CHF 4226 for Treating Patients With COPD

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects

Lamictal in the Treatment of Post-Herpetic Neuralgia

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Stimulation of the Thalamus for Arousal Restoral in Temporal Lobe Epilepsy